search
Back to results

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee

Primary Purpose

Osteoarthritis of Knee

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Pelubiprofen CR 45mg tab.
Aceclofenac 100mg tab.
Sponsored by
Daewon Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis of Knee

Eligibility Criteria

35 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • both male and female who is over 35year-old and below 80year-old
  • patient who diagnosed as Kellgren & Lawrence stage I~III by X-ray
  • osteoarthritis patient who is stable within 3months form starting this clinical trial
  • patient who is over 40mm in 100mm Pain VAS at Visit 2
  • patient who agreed to participate this clinical trial spontaneously

Exclusion Criteria:

  • second osteoarthritis
  • patient who has inflammatory disease which can effect efficacy outcomes such as bursitis, tenosynovitis, rheumatoid arthritis, etc.
  • patient who diagnosed as gastric ulcer or GI disease by esophagogastroduodenoscopy
  • patient who had joint surgery within 12months form screening visit of this clinical trial or planned to operate in this clinical trial period
  • patient who has had artificial joint surgery of knee
  • malignant tumor patient
  • patient who has taken Psychopharmaceutical or Narcotic Analgesics over 3months continuously
  • patient who took steroid by oral, inhalation or intraarticular injection within 3months form screening visit of this clinical trial
  • patient who took intraarticular hyaluronic acid injection of knee within 2months form screening visit of this clinical trial
  • patient who cannot take NSAIDs because of disease or medicine
  • allergy of aspirin of other NSAIDs
  • patient who has to handle his/her pain by or for CABG
  • galactose intolerance, Lactose Intolerance or glucose-galactose malabsorption
  • inflammatory bowel disease such as ulcerative colitis or Crohn's disease
  • moderate renal disease
  • moderate hepatic disease
  • moderate hypertension(SBP=>160mmHg, DBP=>100mmHg)
  • female who consents to contracept
  • patient who is not appropriate for this clinical trial

Sites / Locations

  • Inha university hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

test

reference

Arm Description

Outcomes

Primary Outcome Measures

Change from baseline 100mm Pain VAS at 4weeks

Secondary Outcome Measures

Change from baseline 100mm Pain VAS at 2weeks
Change from baseline K-WOMAC Scale at 2weeks and 4weeks
Patient Global Assessment

Full Information

First Posted
October 12, 2015
Last Updated
October 7, 2016
Sponsor
Daewon Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02682524
Brief Title
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daewon Pharmaceutical Co., Ltd.

4. Oversight

5. Study Description

Brief Summary
A multicenter, randomized, double-blinded, parallel, active-controlled, phase IV clinical trial to evaluate the efficacy and safety of PlbCR and aceclofenac in the treatment of patients with osteoarthritis of the knee

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of Knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
191 (Actual)

8. Arms, Groups, and Interventions

Arm Title
test
Arm Type
Active Comparator
Arm Title
reference
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Pelubiprofen CR 45mg tab.
Intervention Type
Drug
Intervention Name(s)
Aceclofenac 100mg tab.
Primary Outcome Measure Information:
Title
Change from baseline 100mm Pain VAS at 4weeks
Time Frame
4weeks
Secondary Outcome Measure Information:
Title
Change from baseline 100mm Pain VAS at 2weeks
Time Frame
2weeks
Title
Change from baseline K-WOMAC Scale at 2weeks and 4weeks
Time Frame
2weeks, 4weeks
Title
Patient Global Assessment
Time Frame
4weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: both male and female who is over 35year-old and below 80year-old patient who diagnosed as Kellgren & Lawrence stage I~III by X-ray osteoarthritis patient who is stable within 3months form starting this clinical trial patient who is over 40mm in 100mm Pain VAS at Visit 2 patient who agreed to participate this clinical trial spontaneously Exclusion Criteria: second osteoarthritis patient who has inflammatory disease which can effect efficacy outcomes such as bursitis, tenosynovitis, rheumatoid arthritis, etc. patient who diagnosed as gastric ulcer or GI disease by esophagogastroduodenoscopy patient who had joint surgery within 12months form screening visit of this clinical trial or planned to operate in this clinical trial period patient who has had artificial joint surgery of knee malignant tumor patient patient who has taken Psychopharmaceutical or Narcotic Analgesics over 3months continuously patient who took steroid by oral, inhalation or intraarticular injection within 3months form screening visit of this clinical trial patient who took intraarticular hyaluronic acid injection of knee within 2months form screening visit of this clinical trial patient who cannot take NSAIDs because of disease or medicine allergy of aspirin of other NSAIDs patient who has to handle his/her pain by or for CABG galactose intolerance, Lactose Intolerance or glucose-galactose malabsorption inflammatory bowel disease such as ulcerative colitis or Crohn's disease moderate renal disease moderate hepatic disease moderate hypertension(SBP=>160mmHg, DBP=>100mmHg) female who consents to contracept patient who is not appropriate for this clinical trial
Facility Information:
Facility Name
Inha university hospital
City
Chung gu
State/Province
Incheon
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee

We'll reach out to this number within 24 hrs